- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Fall 2012
Case Name |
Date Filed |
Judge |
Drug |
Patent |
Pfizer Inc. v. Roxane Labs., Inc., 12-0593 (S.D. Ohio) |
July 3, 2012 |
Hon. Edmund A. Sargus |
Pristiq®(desvenlafaxine) |
6,673,838 |
Endo Pharma. Inc. v. TWI Pharma., Inc., 12-0848 (D. Del.) |
July 5, 2012 |
Hon. Gregory M. Sleet |
Lidoderm®Patch (lidocaine) |
5,741,510 6,096,334 5,827,529 |
Cubist Pharma., Inc. v. Hospira, Inc., 12-0859 (D. Del.) |
July 9, 2012 |
Hon. Gregory M. Sleet |
Cubicin®(daptomycin for injection) |
8,129,342 |
Shionogi, Inc. v. Nostrum Labs., Inc., 12-4402 (D.N.J.) |
July 13, 2012 |
Hon. Robert B. Kugler |
Fortamet®(metformin hydrochloride extended-release tablets) |
6,099,859 6,866,866 |
Novartis Pharma. Corp. v. Sun Pharma. Indus., Inc., 12-4393 (D.N.J.) |
July 14, 2012 |
Hon. Susan D. Wigenton |
Zometa®(zoledronic acid) Reclast®(zoledronic acid) |
7,932,241 |
Alcon Pharma. Ltd. v. Apotex Inc., 12-0960 (D. Del.) |
July 20, 2012 |
Hon. Sue L. Robinson |
Vigamox®(moxifloxacin hydrochloride ophthalmic solution) |
6,716,830 7,671,070
|
Novartis Pharma. Corp. v. Lupin Ltd., 12-4552 (D.N.J.) |
July 20, 2012 |
Hon. William J. Martini |
Diovan HCT®(valsartan / hydrochlorothiazide tablets) |
6,294,197 |
Celgene Corp. v. Natco Pharma. Ltd., 12-4571 (D.N.J.) |
July 20, 2012 |
Hon. Susan D. Wigenton |
Revlimid®(lenalidomide capsules) |
5,635,517 6,281,230 7,189,740 7,968,569 7,977,357 8,193,219 |
Purdue Pharma L.P. v. Actavis Elizabeth LLC, 12-5615 (S.D.N.Y.) |
July 20, 2012 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended-release tablets) |
8,114,383 |
Alcon Pharma. Ltd. v. Lupin Ltd., 12-0973 (D. Del.) |
July 24, 2012 |
Hon. Sue L. Robinson |
Moxeza®(moxifloxacin hydrochloride ophthalmic solution) |
6,716,830 7,671,070
|
Sunovion Pharma. Inc. v. Watson Pharma., Inc., 12-0993 (D. Del.) |
July 27, 2012 |
Hon. Leonard P. Stark |
Xopenex HFA®(levalbuterol tartrate inhalation aerosol) |
7,256,310 |
Southern Research Institute v. Abon Pharma LLC, 12-4709 (D.N.J.) |
July 27, 2012 |
Hon. William J. Martini |
Clolar®(clofarabine injection) |
5,661,136 |
Meda Pharma. Inc. v. Cadila Healthcare Ltd., 12-4719 (D.N.J.) |
July 27, 2012 |
Hon. Michael A. Shipp |
Astepro®(azelastine 0.15 % nasal spray) |
8,071,073 |
Galderma Labs., L.P. v. Watson Pharma., Inc., 12-2563 (N.D. Tex.) |
July 27, 2012 |
Hon. Ed Kinkeade |
Epiduo®(adapalene / benzoyl peroxide gel) |
8,071,644 8,080,537 8,129,362 |
Millenium Pharma. Inc. v. Sandoz Inc., 12-1011 (D. Del.) |
Aug. 2, 2012 |
Hon. Gregory M. Sleet |
Velcade®(bortezomib injection) |
6,713,446 6,958,319 |
Astrazeneca Pharma. LP v. Amneal Pharma., LLC, 12-4841 (D.N.J.) |
Aug. 2, 2012 |
Hon. Joel A Pisano |
Seroquel XR®(quetiapine fumarate extended-release tablets) |
5,948,437 |
Nycomed Gmbh v. Apotex Inc., 12-1073 (S.D. Ind.) |
Aug. 2, 2012 |
Hon. Tanya W. Pratt |
Omnaris®(ciclesonide nasal spray) |
6,767,901 6,939,559 7,235,247 |
Cumberland Pharma. Inc. v. Perrigo Co., 12-6327 (N.D. Ill.) |
Aug. 9, 2012 |
Hon. Ruben Castillo |
Acetadote®(acetylcysteine intravenous) |
8,148,356 |
Janssen Pharma., Inc. v. Glenmark Generics Ltd., 12-5009 (D.N.J.) |
Aug. 9, 2012 |
Hon. Stanley R. Chessler |
Ortho Tri-Cyclen®LO (norgestimate / ethinyl estradiol) |
6,214,815 |
Luitpold Pharma., Inc. v. Amneal Pharma., LLC, 12-5064 (D.N.J.) |
Aug. 10, 2012 |
Hon. Joel A. Pisano |
Sprix®(ketorolac tromethamine nasal spray) |
6,333,044 |
Santarus, Inc. v. Dr. Reddy’s Labs. Inc., 12-5202 (D.N.J.) |
Aug. 15, 2012 |
Hon. Peter G. Sheridan |
Zegerid®(omeprazole / sodium bicarbonate capsules) |
6,699,885 6,489,346 6,645,988 7,399,772 |
Gilead Sciences, Inc. v. Lupin Ltd., 12-6293 (S.D.N.Y.) |
Aug. 16, 2012 |
Hon. Richard J. Sullivan |
Emtriva®(emtricitabine capsules) |
6,642,245 6,703,396 |
Merck Sharp & Dohme Corp. v. Watson Labs., Inc., 12-5228 (D.N.J.) |
Aug. 20, 2012 |
Hon. Freda L. Wolfson |
Propecia®(finasteride tablets) |
5,571,817 5,547,957 |
Gilead Sciences, Inc. v. Cipla Ltd., 12-6350 (S.D.N.Y.) |
Aug. 20, 2012 |
Hon. Richard J. Sullivan |
Emtriva®(emtricitabine capsules) |
6,642,245 6,703,396 |
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. v. Actavis South Atlantic LLC, 12-1061 (D. Del.) |
Aug. 21, 2012 |
Hon. Leonard P. Stark |
Oleptro®(trazodone hydrochloride extended-release tablets) |
8,133,893 |
ViiV Healthcare Co. v. Mylan Inc., 12-1065 (D. Del.) |
Aug. 22, 2012 |
Hon. Richard G. Andrews |
Lexiva®(fosamprenavir calcium tablets) |
6,436,989 |
Purdue Pharma. Products L.P. v. Actavis Elizabeth LLC, 12-5311 (D.N.J.) |
Aug. 23, 2012 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate tablets) |
7,682,628 |
Janssen Products, L.P. v. Lupin Ltd., 12-5358 (D.N.J.) |
Aug. 24, 2012 |
Hon. William H. Walls |
Prezista®(darunavir tablets) |
RE43,596 |
Purdue Pharma. Products L.P. v. Watson Pharma., Inc., 12-5390 (D.N.J.) |
Aug. 27, 2012 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate tablets) |
7,682,628 |
Merck & Co., Inc. v. Sun Pharma. Indus., Ltd., 12-5374 (D.N.J.) |
Aug. 27, 2012 |
Hon. Freda L. Wolfson |
Ganirelix Acetate Injection |
5,757,082 6,653,286 |
Mallinckrodt, LLC v. Apotex Inc., 12-1087 |
Aug. 30, 2012 |
Hon. Mary Pat Thynge |
Pennsaid®(diclofenac sodium topical solution) |
8,217,078 |
AbbVie, Inc. v. Amneal Pharma., LLC, 12-1088 (D. Del.) |
Aug. 30, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended-release tablets) |
6,080,428 |
GlaxoSmithKline LLC v. Apotex Inc., 12-1090 (D. Del.) |
Aug. 31, 2012 |
Hon. Richard G. Andrews |
Avodart®(dutasteride capsules) |
5,565,467 |
Medicis Pharma. Corp. v. Actavis Mid Atlantic LLC, 12-1091 (D. Del.) |
Aug. 31, 2012 |
Hon. Leonard P. Stark |
Zyclara®(imiquimod) Cream (3.75%) |
8,236,816 |
Teva Branded Pharma. Products R&D, Inc. v. Perrigo Pharma. Co., 12-1101 (D. Del.) |
Sept. 5, 2012 |
Hon. Gregory M. Sleet |
ProAir®HFA (albuterol sulfate) Inhalation Aerosol |
7,105,152 7,566,445 |
Novartis Pharma. Corp. v. Apotex Inc., 12-5574 (D.N.J.) |
Sept. 6, 2012 |
Hon. Jose L. Linares |
Lotrel®(amlodipine / benazepril hydrochloride capsules) |
6,162,802 |
Salix Pharma., Inc. v. Lupin Ltd., 12-1104 (D. Del.) |
Sept. 7, 2012 |
Hon. Gregory M. Sleet |
Apriso®(mesalamine extended-release capsules) |
6,551,620 |
Salix Pharma., Inc. v. Lupin Ltd., 12-2708 (D. Md.) |
Sept. 10, 2012 |
Hon. William D. Quarles, Jr. |
Apriso®(mesalamine extended-release capsules) |
6,551,620 |
Otsuka Pharma. Co., Ltd. v. Apotex Corp., 12-5645 (D.N.J.) |
Sept. 10, 2012 |
Hon. Mary L. Cooper |
Abilify®(aripiprazole oral solution) |
6,977,257 5,006,528 |
Upsher-Smith Labs., Inc. v. Auxilium Pharma., Inc., 12-5648 (D.N.J.) |
Sept. 10, 2012 |
Hon. Jose L. Linares |
Testim®1% (testosterone gel) |
7,608,605 7,608,606 7,608,607 7,608,608 7,608,609 7,608,610 7,935,690 8,063,029 |
Purdue Pharma. Products L.P. v. Novel Labs., Inc., 12-5650 (D.N.J.) |
Sept. 10, 2012 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate tablets) |
7,682,628 |
Braintree Labs., Inc. v. Cypress Pharma., Inc., 12-6851 (S.D.N.Y.) |
Sept. 11, 2012 |
Hon. Alison J. Nathan |
Suprep®(sodium sulfate / potassium sulfate / magnesium sulfate oral solution) |
6,946,149 |
Avanir Pharma., Inc. v. Actavis South Atlantic, LLC, 12-1122 (D. Del.) |
Sept. 12, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide / quinidine sulfate capsules) |
8,227,484 |
Avanir Pharma., Inc. v. Par Pharma., Inc., 12-1123 (D. Del.) |
Sept. 12, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide / quinidine sulfate capsules) |
8,227,484 |
Avanir Pharma., Inc. v. Watson Pharma., Inc., 12-1124 (D. Del.) |
Sept. 12, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide / quinidine sulfate capsules) |
8,227,484 |
Avanir Pharma., Inc. v. Wockhardt Ltd., 12-1125 (D. Del.) |
Sept. 12, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide / quinidine sulfate capsules) |
8,227,484 |
Actelion Pharma. Ltd. v. Apotex Inc., 12-5743 (D.N.J.) |
Sept. 14, 2012 |
Hon. Noel L. Hillman |
Tracleer®(bosentan tablets) |
5,292,740 |
Otsuka Pharma. Co., Ltd. v. Silarx Pharma., Inc., 12-5809 (D.N.J.) |
Sept. 14, 2012 |
Hon. Mary L. Cooper |
Abilify®(aripiprazole oral solution) |
6,977,257 |
Cubist Pharma., Inc. v. Hospira, Inc., 12-1142 (D. Del.) |
Sept. 17, 2012 |
Hon. Gregory M. Sleet |
Cubicin®(daptomycin for injection) |
6,468,967 6,852,689 RE39,071 8,058,238 8,129,342 |
Merck Sharp & Dohme Corp. v. Sandoz Inc., 12-6077 (D.N.J.) |
Sept. 27, 2012 |
Hon. Jose L. Linares |
Zetia®(ezetimibe tablets) |
RE42,461 5,846,966 7,030,106 7,612,058 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.